Speakers

Adrian Spillmann

Agnieszka Deeg-Tyburska

Andre Andrade

Anna Wolters-Hoehne

Anna is a highly experienced patent litigator advising primarily life sciences clients in global patent disputes. With about 20 years of practice in leading and coordinating high profile patent cases Anna develops both offensive and defensive patent strategies for her clients to protect their product portfolio nationally and in an international context.

Anna’s long-standing expertise covers patent infringement and preliminary injunction proceedings as well as patent damages proceedings before the German courts. She also advises on national compulsory licence cases and nullity actions as well as EPO opposition proceedings and the UPC. Anna regularly coordinates international patent disputes and advises clients in particular from the innovative pharmaceutical and medical device industries. 

Betsy Flanagan

Boris Andrejas

Cecile Teles

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

Christina Brown-Marshall

Christof Bull

Claudia Milbradt

Denis Schertenleib

Dorian Immler

Elodie Ferraty

Filipe Pedro

Fritz Gerritzen

Geoff Biegler

Hilary Pioro

Isobel Barry

Jiri Slavik

Julia Pike

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

Katherine Helm

Kaushal Joshi

Laila Beynon

Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

Manja Epping

As a lawyer specialising in pharmaceutical and IP law, Manja has been advising pharmaceutical and biotechnology companies, medical device manufacturers, and food producers on all matters relating to intellectual property and regulatory questions for many years. One of her areas of expertise is regulatory data and market protection as well as orphan drug exclusivity, where she has a track record of representing clients before German and EU courts. Another focus of her practice involves advising clients on complex contractual projects, in particular, research and development cooperations, manufacturing agreements, distribution agreements and licence agreements.

Margaret O'Gara

Margaret is a French and European patent attorney currently heading IP at a late development stage biotech in Paris, called Nanobiotix.

She started her professional career as a researcher in the pharma industry in the UK and France, before moving into patents in 2004.

Since then she has worked both in-house and in IP firms and spent nearly ten years with Santarelli before taking the IP position at Nanobiotix early 2020. Margaret has considerable experience in all aspects of European patent prosecution, and post grant proceedings, as well as strategies for filing new applications . She is interested in data exclusivity and prolonging the protection of innovative products.

Marius-Benjamin Schneider

Martin Schmidt

Michal Porubsky

Nicholas Mitrokostas

Nick is the Managing Partner of the Boston office and an experienced Life Sciences trial attorney who focuses on representing innovator companies in intellectual property, trade secret, licensing and antitrust disputes. A litigator known for his trial skills, Nick has been lead counsel and gone to trial in dozens of ANDA and BPCIA litigations and has extensive experience representing clients in the pharmaceutical, biotechnology, and medical device industries in federal and state courts as well as before the Patent Trial and Appeal Board (PTAB).  Nick also has expertise in counseling emerging and small and mid-cap Life Sciences companies in late stage drug development on issues pertaining to patent and regulatory exclusivities including patent term extension (PTE), patent listing requirements, and pre-commercial and launch assessments and litigation risks. 

Patrick Heckeler

Pedro Roman

Roberto Romandini

Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich.  Since 2019 he has been a legal member at the Boards of Appeal at the EPO. 

Sabine Klepsch

Sherry Yao

Stefanie Kies

Suzanne Renes

Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.

Tobias Wuttke